Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin.
Author(s): Gulseren A, Peyman B, Pinar A
Affiliation(s): Physical Medicine and Rehabilitation, Marmara University School of Medicine, Instanbul, Turkey. firstname.lastname@example.org
Publication date & source: 2011-06, Panminerva Med., 53(2):75-80.
Publication type: Randomized Controlled Trial
AIM: The aim of this study was to evaluate the effect of risedronate treatment on OPG, C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin (OC), deoxypyridinoline (DPD), and to establish the correlation of OPG levels with other bone turnover markers. METHODS: Eighty postmenopausal osteoporotic patients were randomized into two groups. In the first group, 37 patients received 35 mg of risedronate once a week, and 600 mg of elementary calcium with 400 IU of vitamin D per day. In the second group, 34 patients received only 600 mg of elementary calcium with 400 IU of vitamin D per day. OPG, OC, CTX and DPD levels were measured at baseline, then at 1, 3 and 6 months of treatment. RESULTS: OPG levels were significantly reduced at 1 and 6 months of treatment in both the risedronate and control group (p&lt;0.05, p&lt;0.01, respectively), but no statistically significant difference was detected between the two groups (p&gt;0.05). In the group treated with risedronate, a difference in CTX level was observed at 3 months of treatment, while a difference in DPD and OC levels were observed 6 months of treatment. The baseline OPG levels correlated with age, menopause duration and CTX levels. There was no correlation between OPG levels and the levels of the other markers. CONCLUSION: Our results showed that using risedronate to treat postmenopausal osteoporosis causes no specific changes in OPG levels; thus, measurement of OPG levels as a marker may not be useful in the monitoring of bisphosphonate treatment.